Clinical trial requirements for drugs in China include submitting an application to the National Medical Products Administration (NMPA), conducting Phase I-III trials, and obtaining GCP certification. The trials must adhere to local regulations, involve Chinese clinical trial sites, and provide good clinical safety and efficacy data for evaluation. Approval is needed before marketing authorization can be granted.
